Layer, Chiang, et al. Genome Biology
Qiagen's Alacris Investment Provides Biomarker Pipeline for PCR-Based MDx Assay Panels
As part of its investment in Alacris, Qiagen receives an exclusive option to license biomarkers identified through the company's genomics data-analysis platform and develop them into PCR-based assays for use in molecular diagnostic and theranostic applications or biomedical research.
New to GenomeWeb? Register here quickly.